期刊
CURRENT ALZHEIMER RESEARCH
卷 13, 期 1, 页码 68-83出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1567205012666150921095924
关键词
Adrenergic system; Alzheimer's disease; beta-Adrenergic; Monoaminergic systems; Down syndrome; Dementia; Locus coeruleus
资金
- LuMind Foundation
- Research Down Syndrome
- Alzheimer's Association
- Le Jeune Foundation
Locus coeruleus (LC) neurons in the brainstem send extensive noradrenergic (NE)-ergic terminals to the majority of brain regions, particularly those involved in cognitive function. Both Alzheimer's disease (AD) and Down syndrome (DS) are characterized by similar pathology including significant LC degeneration and dysfunction of the NE-ergic system. Extensive loss of NE-ergic terminals has been linked to alterations in brain regions vital for cognition, mood, and executive function. While the mechanisms by which NE-ergic abnormalities contribute to cognitive dysfunction are not fully understood, emergent evidence suggests that rescue of NE-ergic system can attenuate neuropathology and cognitive decline in both AD and DS. Therapeutic strategies to enhance NE neurotransmission have undergone limited testing. Among those deployed to date are NE reuptake inhibitors, presynaptic alpha-adrenergic receptor antagonists, NE prodrugs, and beta-adrenergic agonists. Here we examine alterations in the NE-ergic system in AD and DS and suggest that NE-ergic system rescue is a plausible treatment strategy for targeting cognitive decline in both disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据